BIOCYTOGEN-B Shares Surge Over 9% in Morning Session on Strong Q1 Earnings

Stock News04-28

BIOCYTOGEN-B (02315) rose more than 9% during early trading. At the time of writing, the stock was up 7.65% to HK$63.35, with a turnover of HK$54.1856 million. The company reported its first-quarter 2026 results, showing revenue of RMB 433 million, a year-on-year increase of 73.68%. Net profit attributable to shareholders reached RMB 104 million, surging 885.41% compared to the same period last year. BIOCYTOGEN-B primarily engages in pharmacological efficacy services and model animal revenue. The significant revenue growth this quarter was mainly attributed to increased demand for pharmacological efficacy services. Notably, the company announced plans to invest approximately RMB 1.6 billion through its wholly-owned subsidiary, Jiangsu Biocytogen Gene Biotechnology Co., Ltd., to construct a model animal and antibody drug research and development base. The project will include approximately 96,000 square meters of animal facilities, 30,000 square meters of laboratory space, and related supporting infrastructure.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133299273?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-28 09:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133299273","market":"us","top_or_hot":-1,"title":"BIOCYTOGEN-B Shares Surge Over 9% in Morning Session on Strong Q1 Earnings","media":"Stock News","content":"<p>BIOCYTOGEN-B (02315) rose more than 9% during early trading. At the time of writing, the stock was up 7.65% to HK$63.35, with a turnover of HK$54.1856 million. The company reported its first-quarter 2026 results, showing revenue of RMB 433 million, a year-on-year increase of 73.68%. Net profit attributable to shareholders reached RMB 104 million, surging 885.41% compared to the same period last year. BIOCYTOGEN-B primarily engages in pharmacological efficacy services and model animal revenue. The significant revenue growth this quarter was mainly attributed to increased demand for pharmacological efficacy services. Notably, the company announced plans to invest approximately RMB 1.6 billion through its wholly-owned subsidiary, Jiangsu Biocytogen Gene Biotechnology Co., Ltd., to construct a model animal and antibody drug research and development base. The project will include approximately 96,000 square meters of animal facilities, 30,000 square meters of laboratory space, and related supporting infrastructure.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOCYTOGEN-B Shares Surge Over 9% in Morning Session on Strong Q1 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOCYTOGEN-B Shares Surge Over 9% in Morning Session on Strong Q1 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-28 09:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BIOCYTOGEN-B (02315) rose more than 9% during early trading. At the time of writing, the stock was up 7.65% to HK$63.35, with a turnover of HK$54.1856 million. The company reported its first-quarter 2026 results, showing revenue of RMB 433 million, a year-on-year increase of 73.68%. Net profit attributable to shareholders reached RMB 104 million, surging 885.41% compared to the same period last year. BIOCYTOGEN-B primarily engages in pharmacological efficacy services and model animal revenue. The significant revenue growth this quarter was mainly attributed to increased demand for pharmacological efficacy services. Notably, the company announced plans to invest approximately RMB 1.6 billion through its wholly-owned subsidiary, Jiangsu Biocytogen Gene Biotechnology Co., Ltd., to construct a model animal and antibody drug research and development base. The project will include approximately 96,000 square meters of animal facilities, 30,000 square meters of laboratory space, and related supporting infrastructure.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1133299273","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133299273","pubTimestamp":1777341425,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BIOCYTOGEN-B (02315) rose more than 9% during early trading. At the time of writing, the stock was up 7.65% to HK$63.35, with a turnover of HK$54.1856 million. The company reported its first-quarter...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688796":"百奥赛图","BK1161":"生物科技","02315":"百奥赛图-B","BK4585":"ETF&股票定投概念","BK0216":"研究试验","VXUS":"国际股票ETF-Vanguard","BK4588":"碎股"},"translate_title":"由于第一季度盈利强劲，百奥赛图-B股价早盘飙升超过9%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688796":1,"02315":1,"VXUS":1},"content_text":"BIOCYTOGEN-B (02315) rose more than 9% during early trading. At the time of writing, the stock was up 7.65% to HK$63.35, with a turnover of HK$54.1856 million. The company reported its first-quarter 2026 results, showing revenue of RMB 433 million, a year-on-year increase of 73.68%. Net profit attributable to shareholders reached RMB 104 million, surging 885.41% compared to the same period last year. BIOCYTOGEN-B primarily engages in pharmacological efficacy services and model animal revenue. The significant revenue growth this quarter was mainly attributed to increased demand for pharmacological efficacy services. Notably, the company announced plans to invest approximately RMB 1.6 billion through its wholly-owned subsidiary, Jiangsu Biocytogen Gene Biotechnology Co., Ltd., to construct a model animal and antibody drug research and development base. The project will include approximately 96,000 square meters of animal facilities, 30,000 square meters of laboratory space, and related supporting infrastructure.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133299273","isCrawlerRequest":true}